Industry News - Tag: Moberg

You can read Premium News stories in full if you have an Annual Subscription to the OTCToolbox website. You can read Basic News stories free of charge.

Moberg is divesting OTC to fund MOB-015
Premium

14 February 2019

Moberg Pharma is divesting its OTC business to two private-equity firms in a cash deal worth SEK1.43 billion (USD155 million). The Swedish company plans to focus on developing and commercialising MOB-015, its novel topical terbinafine formulation for treating nail fungus.

Read the full story